Transitioning Pharmaceutical Phase III Data into Market Exclusivity

Medical Patents Broker Inc.
By Kenneth Pearce, President

Achieving positive Phase III clinical results is a significant milestone. As those in this business are well aware, most regulators indicate that it’s “good news,” but then immediately remind us that they need more.

Most people consider the FDA to be a “bureaucracy.” One definition of bureaucracy, derived in part from a Latin root meaning power, can be as simple as a management organization. In 2026, it also means non-elected government officials administering laws.

Some think bureaucracy solely slows the process down. However, my understanding is that the U.S. Constitution was enacted precisely to “slow things down.” Thank goodness, in America, it takes more than a simple edict of a king to silence the protestors. Depending on your side of the fence, bureaucracy can be good, bad, or neutral.

In the current 2026 regulatory environment, the transition from clinical success to commercial sale requires navigating a precise set of administrative, legal, and manufacturing requirements. If the submission is not pristine, entry to the market is delayed.

According to my sources, the following four stumbling blocks frequently create a detour to market:

Potential Stumbling Blocks

1. PDUFA VII Performance Goals and Information Requests

Under the 2026 PDUFA VII fee schedule, the FDA commits to a 6-month goal for Priority Review and a 10-month goal for Standard Review. However, these are not guaranteed deadlines.

• The Reality: The FDA frequently issues Information Requests (IRs) during the mid-cycle review. If the response is not spot on, an administrative delay slows the process to a crawl. Scientists and specialists rarely agree on everything the first time around, but for the regulator, consensus is mandatory.

2. Orange Book Compliance and FTC Scrutiny

The Federal Trade Commission (FTC) has intensified its oversight of Orange Book patent listings. The agency is currently cracking down on “improperly listed” patents, with those involving drug-delivery devices or secondary components receiving the most intense scrutiny. These legal battles are rarely advantageous for the patent owner and can lead to forced delistings and antitrust investigations.

3. The 60-Day Patent Term Extension (PTE) Window

Once the regulatory review is finalized, the clock starts. The PTE application must be filed within sixty days of the marketing approval mailing date under Hatch-Waxman (35 U.S.C. § 156). If you miss this deadline, up to five extra years of limited monopoly—and the accompanying profits—are lost forever. When this happens, someone’s head will usually roll.

4. Manufacturing Compliance (QMSR 2026)

On February 2, 2026, the FDA officially transitioned to the Quality Management System Regulation (QMSR). This aligns U.S. standards with international ISO 13485:2016 requirements. Before an NDA is approved, the FDA will inspect the manufacturing facility. If the quality systems do not meet these new international standards, the application is stalled. Due diligence in manufacturing is no longer just a best practice; it is a mandate.

The President’s Viewpoint

When interacting with federal and state bureaucracies, I find it’s a business decision to disclose more than, less than, or exactly what is requested by the regulators. Usually, "more" is better to avoid the dreaded Information Request. However, when the “frying pan” of litigation is heated, the fewer words used, the better. Regardless of the angle you pursue, this decision on the submission to the bureaucrats can affect the company’s value for decades.